关注
Fabrizio Bossa
Fabrizio Bossa
Dirigente Medico - Fondazione Casa Sollievo della Sofferenza - IRCCS - San Giovanni Rotondo
在 operapadrepio.it 的电子邮件经过验证
标题
引用次数
引用次数
年份
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
MC Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J ...
983*2019
Ulcerative colitis–risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study
MS Silverberg, JH Cho, JD Rioux, DPB McGovern, J Wu, V Annese, ...
Nature genetics 41 (2), 216-220, 2009
5002009
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
G Monteleone, MF Neurath, S Ardizzone, A Di Sabatino, MC Fantini, ...
New England Journal of Medicine 372 (12), 1104-1113, 2015
4802015
Advanced age is an independent risk factor for severe infections and mortality in patients given anti–tumor necrosis factor therapy for inflammatory bowel disease
M Cottone, A Kohn, M Daperno, A Armuzzi, L Guidi, R D'Inca, F Bossa, ...
Clinical Gastroenterology and Hepatology 9 (1), 30-35, 2011
3782011
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study
C Bezzio, S Saibeni, A Variola, M Allocca, A Massari, V Gerardi, V Casini, ...
Gut 69 (7), 1213-1217, 2020
3502020
Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after ileocolonic resection
M Regueiro, BG Feagan, B Zou, J Johanns, MA Blank, M Chevrier, ...
Gastroenterology 150 (7), 1568-1578, 2016
3262016
Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis
V Annese, MR Valvano, O Palmieri, A Latiano, F Bossa, A Andriulli
World journal of gastroenterology: WJG 12 (23), 3636, 2006
1792006
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between …
BD Juran, GM Hirschfield, P Invernizzi, EJ Atkinson, Y Li, G Xie, R Kosoy, ...
Human molecular genetics 21 (23), 5209-5221, 2012
1762012
Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection
S Ben-Horin, M Margalit, P Bossuyt, J Maul, Y Shapira, D Bojic, ...
Clinical Gastroenterology and Hepatology 7 (9), 981-987, 2009
1572009
The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar
G Fiorino, N Manetti, A Armuzzi, A Orlando, A Variola, S Bonovas, ...
Inflammatory bowel diseases 23 (2), 233-243, 2017
1492017
Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
A Bourrier, F Carrat, JF Colombel, AM Bouvier, V Abitbol, P Marteau, ...
Alimentary pharmacology & therapeutics 43 (2), 252-261, 2016
1402016
Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis
F Carbonnel, JF Colombel, J Filippi, KH Katsanos, L Peyrin-Biroulet, ...
Gastroenterology 150 (2), 380-388. e4, 2016
1382016
Randomised controlled trial of mesalazine in IBS
G Barbara, C Cremon, V Annese, G Basilisco, F Bazzoli, M Bellini, ...
Gut 65 (1), 82-90, 2016
1322016
Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial
F Bossa, S Fiorella, N Caruso, L Accadia, G Napolitano, MR Valvano, ...
Official journal of the American College of Gastroenterology| ACG 102 (3 …, 2007
1152007
Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease
A Latiano, O Palmieri, L Pastorelli, M Vecchi, TT Pizarro, F Bossa, G Merla, ...
PloS one 8 (4), e62144, 2013
1142013
Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD)
M Daperno, M Comberlato, F Bossa, L Biancone, AG Bonanomi, ...
Digestive and Liver Disease 46 (11), 969-973, 2014
1052014
Polymorphisms of tumor necrosis factor-α but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease
S Cucchiara, A Latiano, O Palmieri, RB Canani, R D'Incà, G Guariso, ...
Journal of pediatric gastroenterology and nutrition 44 (2), 171-179, 2007
1052007
Plasma N-glycan signatures are associated with features of inflammatory bowel diseases
F Clerc, M Novokmet, V Dotz, KR Reiding, N de Haan, GSM Kammeijer, ...
Gastroenterology 155 (3), 829-843, 2018
1012018
Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study
A Orlando, E Colombo, A Kohn, L Biancone, F Rizzello, A Viscido, ...
Digestive and liver disease 37 (8), 577-583, 2005
1012005
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis
P Invernizzi, M Ransom, S Raychaudhuri, R Kosoy, A Lleo, R Shigeta, ...
Genes & Immunity 13 (6), 461-468, 2012
952012
系统目前无法执行此操作,请稍后再试。
文章 1–20